Literature DB >> 4716431

Cyclophosphamide therapy in systemic lupus erythematosus and polymyositis.

J F Fries, G C Sharp, H O McDevitt, H R Holman.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4716431     DOI: 10.1002/art.1780160204

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


× No keyword cloud information.
  11 in total

Review 1.  Recognition and management of myositis.

Authors:  P Cherin
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

Review 2.  Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis.

Authors:  Patrick A Gordon; John B Winer; Jessica E Hoogendijk; Ernest H S Choy
Journal:  Cochrane Database Syst Rev       Date:  2012-08-15

Review 3.  Clinical use of immunosuppressive drugs: part I.

Authors:  N L Gerber; A D Steinberg
Journal:  Drugs       Date:  1976       Impact factor: 9.546

Review 4.  Systemic lupus erythematosus.

Authors:  Rajan Madhok; Olivia Wu
Journal:  BMJ Clin Evid       Date:  2009-07-24

5.  Regulation of secondary antibody responses in rodents. I. Potentiation of IgG production by cyclophosphamide.

Authors:  R F Gagnon; I C MacLennan
Journal:  Clin Exp Immunol       Date:  1979-07       Impact factor: 4.330

Review 6.  Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus.

Authors:  Virginia Fernandes Moça Trevisani; Aldemar A Castro; João Ferreira Neves Neto; Alvaro N Atallah
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

7.  Mesna side effects which imitate vasculitis.

Authors:  E Reinhold-Keller; J Mohr; E Christophers; K Nordmann; W L Gross
Journal:  Clin Investig       Date:  1992-08

Review 8.  Immunosuppressive treatment for proliferative lupus nephritis.

Authors:  David J Tunnicliffe; Suetonia C Palmer; Lorna Henderson; Philip Masson; Jonathan C Craig; Allison Tong; Davinder Singh-Grewal; Robert S Flanc; Matthew A Roberts; Angela C Webster; Giovanni Fm Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2018-06-29

9.  Second-line agents in myositis: 1-year factorial trial of additional immunosuppression in patients who have partially responded to steroids.

Authors:  Fowzia Ibrahim; Ernest Choy; Patrick Gordon; Caroline J Doré; Alan Hakim; George Kitas; David Isenberg; Bridget Griffiths; Bryan Lecky; Kuntal Chakravarty; John Winer; Katalin Danko; Robert G Cooper; Beverley White-Alao; David L Scott
Journal:  Rheumatology (Oxford)       Date:  2014-11-27       Impact factor: 7.580

Review 10.  Idiopathic Inflammatory Myopathies: Clinical Approach and Management.

Authors:  Asma Malik; Ghazala Hayat; Junaid S Kalia; Miguel A Guzman
Journal:  Front Neurol       Date:  2016-05-20       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.